{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269696","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.543490+00:00","generated_at":"2026-05-16T23:56:16.415226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026","bullets":["Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.","Cash and equivalents $12.7M at Sept 30, 2025, up from $6.5M at Dec 31, 2024.","Received $9.6M gross proceeds from warrant inducement in September 2025.","Announced top-line results from PRIME clinical study; plans FDA meeting for Gemini registration path.","Net cash used in operations $6.3M for 9 months 2025 vs $14.6M in same period 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269696","json":"https://secwatch.observer/filing/0001193125-25-269696.json","markdown":"https://secwatch.observer/filing/0001193125-25-269696.md","text":"https://secwatch.observer/filing/0001193125-25-269696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/0001193125-25-269696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/revb-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:56:16.415226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}